Hoth Therapeutics says HT-001 met primary endpoint in CLEER-001 study

Hoth Therapeutics (HOTH) announced that its investigational candidate HT-001 met the primary efficacy endpoint in at least one metric in 100% of patients in its ongoing Phase 2a clinical study, CLEER-001, evaluating treatment for epidermal growth factor receptor inhibitor-induced cutaneous toxicities. Phase 2a Trial Highlights: 100% of enrolled patients in open-label cohort achieved at least one primary endpoint of clinical dermatologic improvement; Over 65% reported reductions in pain and pruritus; 0% required dose reduction or discontinuation of their EGFRI therapy; Topical therapy was well tolerated with no serious adverse events. In preclinical rat models co-treated with erlotinib, HT-001 significantly reduced: Dermatitis and alopecia severity; Inflammatory markers including Substance P and neutrophil activity; Disease progression even when HT-001 was introduced after symptom onset.